ResearchMoz.us: Obesity Therapeutics to 2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity

ALBANY, New York, September 4, 2013 /PRNewswire/ --

New Report Added in ResearchMoz Reports Database Obesity Therapeutics to 2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity

ResearchMoz announces that it has published a new study Obesity Therapeutics to 2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity

Researchmoz, the leading business intelligence added new report to its vast collection. "Obesity Therapeutics to 2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity". Obesity is often described as a global endemic, with incidence dramatically increasing over the past decades, particularly in developed countries. Being overweight or obese is a major risk factor in the development of many chronic diseases, including cardiovascular diseases, cancer, and diabetes, of which treatment incurs extensive economic and healthcare costs. Numerous anti-obesity drugs have been approved in the past decade, including Knoll Pharmaceutical's Meridia (sibutramine) and Acomplia (rimonabant), only for them to be removed from the market due to evidence of suicidal thoughts, depression and cardiovascular problems with their long-term use. As such, healthcare professionals have a negative perception of such drugs and do not widely prescribe them, a major barrier to the growth of the anti-obesity therapeutics market. Only orlistat is currently deemed safe for the long-term treatment of obesity; being proven to produce a placebo-adjusted weight-loss average of a limited 3kg. Two anti-obesity drugs were approved in June and July 2012, and A strong enough safety and efficacy (average placebo-adjusted weight loss of 5kg at the medium dose) profile to make a significant impact on the market, providing it is proven safe in long-term-use studies. If proven safe, GBI Research expects the sales of Qsymia and other drugs expected to be approved over the forecast period to increase the market size to $2.7 billion. Although moderate, this is significantly below the market potential given the size of the prevalence population. Optimally safe and effective anti-obesity drugs which overcome healthcare professionals' negative opinions will have to be developed if the size of the market is ever to reflect the prevalence of obesity.

Browse Complete Report with TOC@ http://www.researchmoz.us/obesity-therapeutics-to-2019-safety-concerns-hinder-drug-performance-despite-large-market-opportunity-report.html

Scope

The report analyzes the incidence of obesity, current treatment options, pipeline and market forecasts, and deals surrounding anti-obesity drugs.

The report includes:

• A brief introduction to obesity; detailed analysis of recent, current and projected incidence trends; co-morbidities; economic implications of their treatment; and the current treatment options

• Analysis of the currently marketed anti-obesity drugs, including recent sales figures, safety and efficacy data, and a discussion of each drug's expected performance within the forecast period

• Comprehensive reviews of the pipeline for anti-obesity drugs, including analysis by molecule type and mechanism of action

• Statistical analysis of clinical trial duration, size, and failure rate by Phase and molecule type

• An in-depth forecast model for the anti-obesity drugs market in the US, UK, France, Germany, Italy, Spain and Japan. Each model is based on the anticipated market performance of marketed drugs and those expected to be approved within the forecast period, and takes into account drug cost, efficacy, safety, and likely prescription volumes.

• A detailed discussion of the drivers and barriers for this immature market

Reasons to Buy

The report will enhance your decision-making capability by allowing you to:

• Understand the large number of potential molecular targets for the development of an anti-obesity drug, as well as the strengths, weaknesses, and risks of each drug type

• Gain an in-depth view of the current status of the anti-obesity drug pipeline, including the most common molecular targets and molecule types in development

• Observe the trends in clinical trial duration and size by Phase, molecule type and mechanism of action, and use the clinical trial failure rate analysis to assess the risk profiles of current and future developmental programs

• Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the anti-obesity drugs market

• Analyze current and past deals surrounding anti-obesity drugs, including their value, year of deal and in depth details of the highest value deals

Popular Market Research Reports Report:

Power Rental Market: Many companies that deal in a wide  variety of industries are using power rentals to fulfill their temporary  power requirements. These companies hire a wide range of power  equipment and power services from rental companies to fulfill their  power needs without investing huge amounts for such equipment and  services. This helps these companies in reducing their overall cost of initial investment and saves them from making long term investments.  Many companies are now coming forward  to supply power on rent, thereby increasing the quality of service in  power rentals, which is ultimately enhancing the confidence of buyers in  purchasing energy on rent. Browse Complete Report@ http://www.researchmoz.us/power-rental-market-global-industry-analysis-market-share-size-growth-trends-and-forecast-2012-2018-report.html

Business Process Management(BPM) Market: Research announces that it has a new study on Business Process Management (BPM) Software Market Shares and Forecasts, Worldwide, 2011-2017. The 2011 study has 775 pages, 245 tables and figures. Business Process Management, (BPM) is evolving more sophisticated software that works in cloud computing environments, allowing users at every level to achieve self-provisioning and automate processes that involve collaboration.IBM is the market leader in BPM with a suite of products that improve every year. IBM is able to invest in the product set, improving it as the customer base grows ever larger, spreading the cost of software implementation across the large customer base. Browse Complete Report@ http://www.researchmoz.us/business-process-management-bpm-market-shares-strategies-and-forecasts-worldwide-2011-to-2017-report.html

Global Pet Food Market  : Analysts forecast the Global Pet Food market to grow at a CAGR of 6.35 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increase in urbanization which has increased the purchasing power of people. The Global Pet Food market has also been witnessing a rise in the number of nuclear families. However, health issues faced by pets often restrict people from keeping pets in their homes and could pose a challenge to the growth of this market. Browse Complete Report@ http://www.researchmoz.us/global-pet-food-market-2012-2016-report.html

Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Etiology and Pathophysiology
2.2 Classification
2.3 Epidemiology
2.3.1 The US
2.3.2 Obesity in the Top Five European Markets
2.3.3 Japan
2.4 Comorbidities
2.4.1 Type 2 Diabetes
2.4.2 Hypertension
2.4.3 Dyslipidemia
2.4.4 Respiratory Problems
2.4.5 Osteoarthritis
2.4.6 Cancer Risk
2.5 Economic Burden
2.6 Current Therapy Options
2.6.1 Lifestyle and Behavioral Modifications
2.6.2 Bariatric Surgery
2.6.3 Pharmacotherapy
2.6.4 Treatment Algorithms and Prescription Habits
2.6.5 Method of Determining Treatment Effectiveness
2.7 Why Develop Therapeutic Anti-obesity Drugs?
2.8 GBI Research Report Guidance

3 Marketed Products
3.1 Amphetamine-like Drugs
3.1.1 Overview
3.1.2 Efficacy Profile
3.1.3 Safety Profile
3.2 Qsymia, Vivus, Inc.
3.2.1 Overview
3.2.2 Efficacy Profile
3.2.3 Safety Profile
3.2.4 Discussion
3.3 Orlistat
3.3.1 Overview
3.3.2 Efficacy Profile
3.3.3 Safety Profile
3.3.4 Discussion
3.4 Belviq, Arena Pharmaceuticals
3.4.1 Introduction
3.4.2 Efficacy Profile
3.4.3 Safety Profile
3.4.4 Discussion
3.5 Low Long-term Success Rate of Marketed Anti-Obesity Drugs
3.6 Discussion

4 Pipeline
4.1 Overview of Pipeline by Phase, Molecule Type and Molecular Target
4.2 Clinical Trial Duration and Size
4.2.1 Clinical Trial Duration
4.2.2 Clinical Trial Size
4.3 Clinical Trial Failure, Attrition Rate and Reasons for Clinical Trial Failure
4.4 Primary and Secondary Endpoints
4.5 Late-stage Drugs of the Developmental Pipeline
4.5.1 Contrave, Orexigen Therapeutics
4.5.2 Cametor, Norgine BV
4.5.3 Victoza, Novo Nordisk
4.5.4 Tesofensine (NeuroSearch)
4.6 Discussion

5 Market Forecasts
5.1 Global Market
5.2 The US
5.2.1 Epidemiology and Treatment Usage Patterns
5.2.2 Annual Cost of Therapy
5.2.3 Market Size
5.3 Europe
5.3.1 Treatment Usage Patterns
5.3.2 Annual Cost of Therapy
5.3.3 Market Size
5.4 Japan
5.4.1 Treatment Usage Patterns
5.4.2 Annual Cost of Therapy
5.4.3 Market Forecast
5.5 Discussion
5.6 Drivers and Barriers of the Anti-obesity Market
5.7 Obesity Market Drivers
5.7.1 Obesity is a Very Prevalent Disease with Large Potential Target Populations Globally
5.7.2 Recent Approval of Qsymia to Drive Market Growth Providing its Long-term Safety is Proved
5.7.3 Diversification of Molecular Targets
5.8 Obesity Market Barriers
5.8.1 Low Treatment Rate
5.8.2 Reimbursement Issues

6 Licensing and Co-Development Deals
6.1 Licensing Deals
6.1.1 EMD Serono Enters into Collaboration and Licensing Agreement with Theratechnologies
6.1.2 Amylin Pharma Enters into Licensing Agreement with Takeda Pharma
6.1.3 Palatin Technologies Extends License Agreement with AstraZeneca
6.1.4 Zealand Pharma Enters into Licensing and Collaboration Agreement with Boehringer

Ingelheim
6.2 Co-development Deals
6.2.1 Isis Enters into Collaboration Agreement with Ortho-McNeil
6.2.2 Orexigen Therapeutics Enters into Co-development Agreement with Takeda Pharma for

Contrave
7 Appendix
7.1 References
7.2 Abbreviations
7.3 All Pipeline Drugs by Phase
7.3.1 Discovery
7.3.2 Preclinical
7.3.3 Phase I
7.3.4 Phase II
7.3.5 Phase III
7.3.6 Pre-Registration
7.4 Market Forecasts to 2019
7.4.1 Global
7.4.2 The US
7.4.3 UK
7.4.4 France
7.4.5 Germany
7.4.6 Italy
7.4.7 Spain
7.4.8 Japan
7.5 Methodology
7.6 Secondary Research
7.7 Therapeutic Landscape
7.8 Epidemiology-Based Forecasting
7.9 Market Size by Geography
7.10 Pipeline Analysis
7.11 Contact Us
7.12 Disclaimer

Browse Complete Report with TOC@ http://www.researchmoz.us/obesity-therapeutics-to-2019-safety-concerns-hinder-drug-performance-despite-large-market-opportunity-report.html

About Us

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-997-4948

Email: sales@researchmoz.com
http://www.researchmoz.us/
http://www.researchmoz.blogspot.com/


SOURCE ResearchMoz




Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.